Unicycive Therapeutics stock: Q3 loss widens to USD 7.0 million
Published on 11/20/2026 at 00:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey developments at Unicycive
- The FDA set March 25, 2027, as the target action date for the resubmitted OLC application.
- Commercial launch preparations are increasing general and administrative spending.
- Cash, cash equivalents and marketable securities totaled USD 59 million at September 30.
Unicycive Therapeutics reported its third-quarter 2026 results on November 16, showing a higher net loss as the biotechnology company prepares for a potential launch of oxylanthanum carbonate. The company also highlighted the U.S. Food and Drug Administration's acceptance of its resubmitted application and a March 25, 2027, target action date.
Loss expands with launch spending
Net loss attributable to common stockholders reached USD 7.0 million, or USD 0.25 per share, for the quarter ended September 30. A year earlier, the loss was USD 6.0 million, or USD 0.33 per share. The narrower per-share loss came as the weighted-average share count increased.
Research and development expense fell to USD 2.2 million from USD 3.0 million. General and administrative expense rose to USD 6.6 million from USD 4.4 million, including USD 1.4 million for commercial launch preparation. Unicycive attributed the larger net loss primarily to those launch-related expenses.
FDA review sets next milestone
The FDA accepted Unicycive's resubmitted New Drug Application for oxylanthanum carbonate, or OLC, in October and assigned the March 25, 2027, Prescription Drug User Fee Act target action date. OLC is being developed to treat hyperphosphatemia in dialysis patients with chronic kidney disease. Unicycive said the company is continuing preparations for a potential U.S. launch while the application remains under review.
As of September 30, cash, cash equivalents and marketable securities totaled USD 59 million. The company said that balance should support operations beyond 2027, including anticipated expenses for a potential OLC launch.
Business model and competitors
Unicycive Therapeutics is a Mountain View, California-based biotechnology company developing treatments for kidney diseases. Its lead investigational product is OLC, a phosphate-binding agent for dialysis patients with chronic kidney disease, while UNI-494 is being developed for conditions related to acute kidney injury. The company focuses on drug development and potential commercialization in the U.S. kidney-care market.
Unicycive Therapeutics at a glance
- Company: Unicycive Therapeutics, Inc.
- ISIN: US90466Y2028
- Ticker: UNCY
- Exchange: Nasdaq
- Lead program: Oxylanthanum carbonate for hyperphosphatemia in dialysis patients
- FDA target action date: March 25, 2027
U.S. biotechnology stocks remain focused on clinical and regulatory milestones; the broader market environment is covered in current S&P 500 market coverage.
Further updates and analysis are available in more news and analyses on Unicycive Therapeutics stock.
